# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
The company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and se...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintain...
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of ...